Motif Bio PLC Jefferies Global Healthcare Conference
May 31 2018 - 2:00AM
RNS Non-Regulatory
TIDMMTFB
Motif Bio PLC
31 May 2018
Motif Bio plc
("Motif Bio" or the "Company")
Motif Bio to present at Jefferies Global Healthcare Conference
in New York
Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage
biopharmaceutical company specialising in developing novel
antibiotics, announced today that the Company will give a company
presentation and meet with investors at the following event:
Jefferies Global Healthcare Conference
June 5-8, 2018
New York, NY USA
Graham Lumsden, Chief Executive Officer, will give a company
presentation on June 8(th) at 10:30 AM ET. The presentation will be
webcast, available live and as a replay in the Investors section of
the Company's website. The Company also expects to participate in
one-on-one meetings during the event.
The conference will feature an extensive range of public and
private healthcare companies across the biopharmaceuticals, life
sciences, healthcare services, healthcare IT and medical technology
sectors. This global gathering of leading executives, institutional
investors, private equity investors and VCs will address near- and
long-term investment opportunities and discuss the mechanisms
driving healthcare in the U.S. and internationally.
For further information please contact:
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief Executive
Officer)
Walbrook PR Ltd. (UK FINANCIAL
PR & IR) +44 (0) 20 7933 8780
Paul McManus/Helen Cresswell/Lianne
Cawthorne
MC Services AG (EUROPEAN
IR) +49 (0)89 210 2280
Raimund Gabriel raimund.gabriel@mc-services.eu
Solebury Trout (US IR) + 1 (646) 378-2936
Meggie Purcell mpurcell@troutgroup.com
Russo Partners (US PR) +1 (858) 717-2310 or
+1 (212) 845 4272
David Schull david.schull@russopartnersllc.com
Travis Kruse, Ph.D. travis.kruse@russopartnersllc.com
Notes to Editors
About Motif Bio
Motif Bio plc (AIM/NASDAQ: MTFB) is a clinical-stage
biopharmaceutical company focused on developing novel antibiotics
for hospitalised patients and designed to be effective against
serious and life-threatening infections caused by multi-drug
resistant bacteria, including MRSA. The Company's lead product
candidate is iclaprim. Following positive results from two Phase 3
trials (REVIVE-1 and REVIVE-2), a rolling submission of an NDA with
the U.S. FDA for the treatment of ABSSSI has been initiated and is
expected to be completed in the second quarter of 2018. ABSSSI is
one of the most common bacterial infections, with 3.6 million
patients hospitalised annually in the U.S. The Company believes
that iclaprim may be suitable for first-line empiric therapy in
ABSSSI patients, especially those with renal impairment, with or
without diabetes.
The Company also plans to develop iclaprim for hospital acquired
bacterial pneumonia (HABP), including ventilator associated
bacterial pneumonia (VABP), as there is a high unmet need for new
therapies in this indication. A Phase 2 trial in patients with HABP
has been successfully completed and a Phase 3 trial is being
planned. Additionally, iclaprim has been granted orphan drug
designation by the FDA for the treatment of Staphylococcus aureus
lung infections in patients with cystic fibrosis and is in
preclinical development for this indication.
Iclaprim has received Qualified Infectious Disease Product
(QIDP) designation from the FDA together with Fast Track status.
Upon acceptance by the FDA of an NDA, iclaprim will receive
Priority Review status and, if approved as a New Chemical Entity,
will be eligible for 10 years of market exclusivity in the U.S.
from the date of first approval, under the Generating Antibiotic
Incentives Now Act (the GAIN Act). In Europe, 10 years of market
exclusivity is anticipated.
Forward-Looking Statements
This press release contains forward-looking statements. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. Forward-looking statements
involve known and unknown risks, uncertainties and other important
factors that may cause Motif Bio's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Motif Bio believes that these factors
include, but are not limited to, (i) the timing, progress and the
results of clinical trials for Motif Bio's product candidates, (ii)
the timing, scope or likelihood of regulatory filings and approvals
for Motif Bio's product candidates, (iii) Motif Bio's ability to
successfully commercialise its product candidates, (iv) Motif Bio's
ability to effectively market any product candidates that receive
regulatory approval, (v) Motif Bio's commercialisation, marketing
and manufacturing capabilities and strategy, (vi) Motif Bio's
expectation regarding the safety and efficacy of its product
candidates, (vii) the potential clinical utility and benefits of
Motif Bio's product candidates, (viii) Motif Bio's ability to
advance its product candidates through various stages of
development, especially through pivotal safety and efficacy trials,
(ix) Motif Bio's estimates regarding the potential market
opportunity for its product candidates, and (x) the factors
discussed in the section entitled "Risk Factors" in Motif Bio's
Annual Report on Form 20-F filed with the SEC on April 10, 2018,
which is available on the SEC's web site, www.sec.gov. Motif Bio
undertakes no obligation to update or revise any forward-looking
statements.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAURVORWOAVOAR
(END) Dow Jones Newswires
May 31, 2018 02:00 ET (06:00 GMT)
Motif Bio (LSE:MTFB)
Historical Stock Chart
From Apr 2024 to May 2024
Motif Bio (LSE:MTFB)
Historical Stock Chart
From May 2023 to May 2024